CP-724714 (CAS: 537705-08-1) is a small molecule inhibitor of the insulin-like growth factor 1 receptor (IGF-1R), which has shown potential therapeutic benefits in various types of cancers.
Introduction to CP-724714 CP-724714 is a selective and potent inhibitor of IGF-1R, a tyrosine kinase receptor that plays a crucial role in the regulation of cell growth, differentiation, and survival. The overexpression or activation of IGF-1R has been associated with several oncogenic processes, including tumor growth, angiogenesis, and metastasis. Therefore, IGF-1R inhibitors have been considered as promising cancer therapeutics.
Chemical Name, Molecular Formula, Formula Weight, and CAS No. The chemical name of CP-724714 is (3S,4S)-N-methyl-3-[4-(2-pyridinyl)-3-pyridazinyl]-4-[1,2,4]triazolo[1,5-a]pyridin-7-amine monohydrochloride. The molecular formula of CP-724714 is C16H14N8 HCl, and its formula weight is 348.79 g/mol. The CAS number of CP-724714 is 537705-08-1.
Top 10 Keywords from Google and Synonyms
Synonyms:
Health Benefits of CP-724714 Several studies have suggested that CP-724714 has potential health benefits as an anticancer agent. It targets IGF-1R, which is known to be overexpressed or activated in several types of cancers, including breast cancer, lung cancer, prostate cancer, and sarcoma. By inhibiting IGF-1R, CP-724714 interferes with the signaling pathways involved in tumor growth, invasion, and angiogenesis, and thus may prevent the spread of cancer cells.
Potential Effects of CP-724714 Several preclinical and clinical studies have reported the potential effects of CP-724714 in cancer therapy. In vitro studies have shown that CP-724714 inhibits the proliferation, migration, and invasion of cancer cells, and induces apoptosis or programmed cell death. In vivo studies in animal models have demonstrated that CP-724714 suppresses tumor growth and metastasis, and enhances the efficacy of chemotherapy and radiotherapy.
Product Mechanism CP-724714 acts by selectively inhibiting the tyrosine kinase activity of IGF-1R, which is a transmembrane protein that binds to insulin-like growth factors (IGFs) and activates downstream signaling pathways involved in cell growth, survival, and differentiation. CP-724714 binds to the ATP-binding site of IGF-1R and prevents its autophosphorylation, which leads to the inhibition of downstream signaling cascades, such as PI3K/Akt and MAPK/Erk, involved in cell proliferation, survival, and motility.
Safety of CP-724714 Although CP-724714 has shown promising results in cancer therapy, it may also have potential safety concerns. The toxicity profile of CP-724714 has been evaluated in preclinical studies and clinical trials, and the most common adverse events reported were gastrointestinal disturbances, fatigue, headache, and hematological toxicity. However, the safety and tolerability of CP-724714 may vary depending on the patient population, dose, and treatment schedule.
Side Effects of CP-724714 The most common side effects of CP-724714 reported in clinical trials include nausea, vomiting, diarrhea, fatigue, headache, and myelosuppression. Rare but serious adverse events associated with CP-724714 include liver toxicity, pulmonary embolism, and cardiovascular events. Patients receiving CP-724714 should be monitored for any signs of adverse effects and treated accordingly.
Dosing Information of CP-724714 The dosing regimen of CP-724714 may vary depending on the type and stage of cancer, patient characteristics, and treatment goals. The recommended dose of CP-724714 in clinical trials ranged from 250 mg to 500 mg per day, administered orally once or twice daily. The duration of treatment may also vary depending on the response and tolerance of the patient
